Versant Vantage II GP, L.P. has made a significant move by acquiring a large stake in Lycia Therapeutics, Inc. This acquisition involves over 25 million shares of Series A and Series B Preferred Stock, which automatically converted into common stock upon the closing of Lycia's initial public offering on October 26, 2026. Such a substantial investment indicates Versant's confidence in Lycia's future and may reshape the competitive landscape in the biological products sector.

Background

Versant Vantage II GP, L.P. is a limited partnership based in San Francisco, California. It operates under the Central Index Key (CIK) 0001839790. The firm is involved in venture capital investments, particularly in the life sciences sector. Recent filings include a Form 4 filed on October 28, 2026, detailing ownership changes related to its investment activities.

What the Filing Says

The recent filing, accession number 0001193125-26-436415, reveals that Versant Vantage II GP, L.P. acquired 25,390,410 shares of Series A Preferred Stock and 6,284,597 shares of Series B Preferred Stock. These shares converted into common stock on a one-for-0.221793422 basis during Lycia's IPO. The filing notes that "the shares are held directly by Versant Venture Capital VII, L.P.," emphasizing the interconnected ownership structure.

Impact

This acquisition may significantly impact both Versant and Lycia, enhancing Versant's influence in the biological products market. As a ten percent owner, Versant Vantage II GP, L.P. joins other significant stakeholders in shaping the strategic direction of Lycia Therapeutics. The filing indicates that several entities, including Versant Ventures VII GP, L.P., and Versant Ventures VII GP-GP, LLC, are also involved, suggesting a well-coordinated investment strategy.

What's Next

The filing does not say what happens next, but the acquisition positions Versant Vantage II GP, L.P. to play a crucial role in Lycia's future developments. Stakeholders will be watching closely for any further announcements or strategic moves from both companies.